Indivior PLC’s contingency planning for the potential loss of US market exclusivity for its largest-selling product, sublingual Suboxone Film (buprenorphine/naloxone), includes conserving cash while supporting the commercialization of two newer products, the possible introduction of an authorized generic through its partner, Sandoz International GMBH, and reducing costs.
“The over-riding objectives of the contingency plan are to provide for the commercial success of Sublocade (buprenorphine) extended-release subcutaneous monthly...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
